Abstract
Cancer remains the leading cause of death worldwide and tumor drug resistance markedly diminishes the effectiveness of many treatments. Resistance arises not only from intrinsic factors within cancer cells but also from extrinsic mechanisms within the tumor microenvironment (TME). To address this challenge, researchers have combined stimuli-responsive peptides with nanomaterials capable of responding to endogenous or exogenous signals, thereby overcoming resistance through multiple synergistic mechanisms. This review emphasizes how rational peptide design enhances signal responsiveness and therapeutic accuracy, systematically summarizes recent advances in breaking through tumor drug resistance, and elaborates the advantages and limitations of endogenous and exogenous responsive nanomaterials. Finally, we discuss current challenges and future directions toward promoting clinical translation.

京公网安备11010802044758号
Comments on this article